EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers

Tiffany S Lai, Alex Francoeur, Erica Manrriquez, Puja Venkat, Albert Chang, Michael Douek, Simin Bahrami, Steven S Raman, Sanaz Memarzadeh

Brachytherapy · 2024

DOI: 10.1016/j.brachy.2023.12.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brachytherapy, 2024. Verfasst von Tiffany S Lai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of California Los Angeles, Los Angeles, CA. Electronic address: tlai@mednet.ucla.edu. Hauptthemen laut MEDLINE: Brachytherapy, Genital Neoplasms, Female. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Treatment of recurrent oligometastatic gynecologic malignancy may involve targeted surgery, thermal ablation, or CT-guided high-dose-rate interstitial brachytherapy ablation (CT-HDR-IBTA). The purpose of this study was to describe the safety and efficacy of CT-HDR-IBTA for oligometastatic gynecologic malignancies. METHODS: With institutional review board approval (IRB) approval and compliance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliance, we searched our database to assemble a single-arm study cohort of all patients with oligometastatic gynecologic cancers who underwent CT-HDR-IBTA from 2012-2022 with follow-up. The electronic record was reviewed to determine relevant clinicopathological variables including patient demographics, prior treatments, clinical course, local control, and local and distant recurrence with follow-up imaging. RESULTS: The study cohort comprised 37 lesions in 34 patients treated with CT-HDR-IBTA for recurrent oligometastatic uterine (n = 17), cervix (n = 1), or ovarian cancer (n = 16) with an average lesion size of 2.5 cm with an average patient age of 61.4 years. Each lesion was treated with an average radiation dose of 23.8 Gy in 1.8 fractions and a median follow-up time of 24.0 months. The primary efficacy of CT HDR ITBA was 73% with a median progression-free survival of 8.0 months (95% CI 3.6-12.8 months) and with 58% of patients still alive at 43 months with median overall survival not reached. The rate of Grade 1 adverse events was 22% without any Grade 2, 3 or 4 events. CONCLUSIONS: CT HDR IBTA was safe and effective for treating oligometastatic gynecologic cancers in a heavily pretreated cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrachytherapyGenital Neoplasms, FemaleHumansFemaleMiddle AgedAgedAdultNeoplasm Recurrence, LocalRetrospective StudiesTreatment OutcomeAged, 80 and overTomography, X-Ray ComputedUterine NeoplasmsNeoplasm MetastasisAblation TechniquesUterine Cervical Neoplasms

Stichwörter der Autor:innen

Cervix cancerEndometrial cancerGynecologic cancerInterstitial brachytherapyOligometastatic cancerOvarian cancer

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, University of California Los Angeles, Los Angeles, CA. Electronic address: tlai@mednet.ucla.edu.
  • Department of Obstetrics and Gynecology, University of California Los Angeles, Los Angeles, CA.
  • Dignity Mercy Hospital, Bakersfield, CA.
  • Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA.
  • Department of Radiology, University of California Los Angeles, Los Angeles, CA.

Förderung

  • National Institutes of Health

Zitieren

APA

Lai, T. S., Francoeur, A., Manrriquez, E., Venkat, P., Chang, A., Douek, M., Bahrami, S., Raman, S. S., & Memarzadeh, S. (2024). Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers. Brachytherapy. https://doi.org/10.1016/j.brachy.2023.12.007

Vancouver

Lai TS, Francoeur A, Manrriquez E, Venkat P, Chang A, Douek M, et al. Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers. Brachytherapy. 2024. doi:10.1016/j.brachy.2023.12.007

BibTeX
@article{Lai2024,
  author = {Lai, Tiffany S and Francoeur, Alex and Manrriquez, Erica and Venkat, Puja and Chang, Albert and Douek, Michael and Bahrami, Simin and Raman, Steven S and Memarzadeh, Sanaz},
  title = {Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers},
  journal = {Brachytherapy},
  year = {2024},
  doi = {10.1016/j.brachy.2023.12.007}
}
Kostenlos starten →